Thematics Asset Management Raises Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Thematics Asset Management raised its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 34.8% in the third quarter, Holdings Channel.com reports. The fund owned 246,173 shares of the medical device company’s stock after purchasing an additional 63,495 shares during the period. Thematics Asset Management’s holdings in DexCom were worth $16,503,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Taylor Frigon Capital Management LLC lifted its stake in DexCom by 51.6% during the third quarter. Taylor Frigon Capital Management LLC now owns 32,554 shares of the medical device company’s stock worth $2,182,000 after purchasing an additional 11,075 shares in the last quarter. Brooktree Capital Management purchased a new position in DexCom during the 3rd quarter valued at about $683,000. National Pension Service boosted its stake in shares of DexCom by 4.1% in the third quarter. National Pension Service now owns 949,743 shares of the medical device company’s stock valued at $63,671,000 after purchasing an additional 37,363 shares during the period. Intact Investment Management Inc. acquired a new position in shares of DexCom in the third quarter worth $650,000. Finally, Waters Parkerson & CO. LLC increased its holdings in DexCom by 4.2% during the 2nd quarter. Waters Parkerson & CO. LLC now owns 272,641 shares of the medical device company’s stock worth $30,912,000 after purchasing an additional 10,892 shares during the period. 97.75% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the sale, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. The trade was a 0.28 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Sadie Stern sold 426 shares of DexCom stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the sale, the executive vice president now owns 75,451 shares in the company, valued at $5,217,436.65. This represents a 0.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 5,431 shares of company stock valued at $399,319 in the last three months. Corporate insiders own 0.30% of the company’s stock.

DexCom Trading Up 6.9 %

DexCom stock traded up $5.00 during trading on Tuesday, reaching $77.83. The company had a trading volume of 6,579,325 shares, compared to its average volume of 3,939,276. The firm has a market capitalization of $30.40 billion, a price-to-earnings ratio of 46.60, a PEG ratio of 2.23 and a beta of 1.17. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. The stock’s 50 day moving average price is $70.76 and its two-hundred day moving average price is $88.93. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00.

Wall Street Analysts Forecast Growth

DXCM has been the topic of a number of recent analyst reports. Raymond James dropped their price objective on DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a report on Friday, October 25th. Barclays decreased their target price on DexCom from $138.00 to $113.00 and set an “equal weight” rating for the company in a research report on Monday, July 29th. StockNews.com lowered DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. Oppenheimer decreased their price objective on DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Finally, Sanford C. Bernstein upped their price target on shares of DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a research report on Friday, October 25th. Seven investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $104.59.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.